Bioxytran sees positive dose optimization, moves to Phase 3 trial for ProLectin-M with 408 patients, targeting viral infected outpatients.
Unusual Whales
A company has begun regulatory discussions with the Central Drugs Standard Control Organization (CDSCO). They are planning to conduct a pivotal study with 408 patients focusing on standard-risk outpatients infected with various viruses.
